The UW Initiative to End Alzheimer’s (IEA) is pleased to announce the IEA Innovation Fund, providing project support for researchers from the Wisconsin Alzheimer’s Disease Research Center (ADRC) or Wisconsin Alzheimer’s Institute (WAI). The IEA Innovation Fund will help advance the University of Wisconsin–Madison’s Alzheimer’s disease researchers’ most promising ideas by providing an open door to funding opportunities that foster translational, innovative and inclusive advancements in Alzheimer’s disease research.
Month: February 2023
A closer look at lecanemab
In January, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway to treat Alzheimer’s disease. Nathaniel Chin, MD, recently interviewed Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to inform people about the research behind the new Alzheimer’s treatment, the drug’s benefits and risks, and more.
UW study focuses on Alzheimer’s disease treatment and prevention in the Black community
Carey Gleason, PhD, MS, and her research team’s African Americans Fighting Alzheimer’s in Midlife (AA-FAIM) study is entering its second, five-year cycle and they are focused on making Alzheimer’s research more inclusive.
Dr. Maria Mora Pinzon appointed to assistant professor
Maria Mora Pinzon, MD, MS, FACPM, was recently appointed to assistant professor on the tenure track in the Division of Geriatrics and Gerontology at the University of Wisconsin School of Medicine and Public Health, where she will continue working with the Wisconsin Alzheimer’s Institute and expand her research program.